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Severe sepsis is a time critical condition which is known to have a high mortality rate. Evidence 
suggests that early diagnosis and early administration of antibiotics can reduce morbidity and 
mortality from sepsis. The prehospital phase of emergency medical care may provide the earliest 
opportunity for identification of sepsis and delivery of life-saving treatment for patients. We aimed to 
assess the feasibility of (1) paramedics recognising and screening patients for severe sepsis, collecting 
blood cultures and administering intravenous antibiotics; and (2) trial methods in order to decide 
whether a fully-powered trial should be undertaken to determine safety and effectiveness of this 
intervention. Paramedics were trained in using a sepsis screening tool, aseptic blood culture collection 
and administration of intravenous antibiotics. If sepsis was suspected, paramedics randomly allocated 
patients to intervention or usual care using scratchcards. Patients were followed up at 90 days using 
linked anonymised data to capture length of hospital admission and mortality. We collected self-
reported health-related quality of life at 90 days. We pre-specified criteria for deciding whether to 
progress to a fully-powered trial based on: recruitment of paramedics and patients; delivery of the 
intervention; retrieval of outcome data; safety; acceptability; and success of anonymised follow-up. 
Seventy-four of the 104 (71.2%) eligible paramedics agreed to take part and 54 completed their 
training (51.9%). Of 159 eligible patients, 146 (92%) were recognised as eligible by study paramedics, 
and 118 were randomised (74% of eligible patients, or 81% of those recognised as eligible). Four 
patients subsequently dissented to be included in the trial (3%), leaving 114 patients recruited to 
follow-up. All recruited patients were matched to routine data outcomes in the Secure Anonymised 
Information Linkage Databank. Ninety of the 114 (79%) recruited patients had sepsis or a likely 
bacterial infection recorded in ED. There was no evidence of any difference between groups in patient 
satisfaction, and no adverse reactions reported. There were no statistically significant differences 
between intervention and control groups in Serious Adverse Events (ICU admissions; deaths). This 
feasibility study met its pre-determined progression criteria; an application will therefore be prepared 
and submitted for funding for a fully-powered multi-centre randomised trial.
Trial registration: ISRCTN36856873 sought 16th May 2017; https:// doi. org/ 10. 1186/ ISRCT N3685 6873
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Background. Sepsis is a life threatening condition which requires rapid recognition and treatment in order 
to not only prevent death, but also to minimise the damage that is does to a person’s body. Sepsis can lead to 
organ and limb damage, leaving patients with significant morbidity if they survive. Approximately 44,000 people 
die of sepsis every year in the  UK1—more than are diagnosed with bowel cancer  annually2.
There is evidence that administering antibiotics early reduces complications and death from  sepsis3–6. It is 
known that recognition of sepsis by Emergency Medical Service (EMS) personnel in the prehospital phase of 
care leads to faster diagnosis and treatment in the Emergency Department (ED)7,8. Around half of patients with 
sepsis are conveyed to the ED by  ambulance9,10, with an average prehospital care time of 45  min11, therefore, 
EMS personnel can play a significant role in the management of sepsis.
Early recognition and management of sepsis by EMS personnel offers a potentially valuable opportunity 
to deliver interventions early, but the evidence base to support the use of prehospital antibiotics is  weak12,13. 
In 2016/17, when this feasibility study was first conceived, there was no well-defined prehospital protocol for 
management of sepsis in the UK. In 2019, the Joint Royal Colleges Ambulance Liaison Committee (JRCALC), 
issued a prehospital clinical practice guideline for the management of sepsis, which recognises the potential 
value of pre-hospital sepsis screening tools, but acknowledges that, to date, none have been validated for  use14.
Aim. To assess the feasibility of paramedics screening patients for severe sepsis, collecting blood cultures 
and administering IV antibiotics, and to assess trial methods to inform the development of a fully-powered 
randomised controlled trial (RCT), to test the clinical and cost-effectiveness of prehospital IV antibiotics, if 
indicated.
Objectives. Intervention development. To work with clinicians, paramedics, pharmacists, and service users 
to develop a prehospital intervention for sepsis, comprising:
• Screening patients for sepsis
• Protocol for collection of blood cultures, administering IV antibiotics, and handover of care to ED
• Training for paramedics to deliver the agreed protocol
Intervention feasibility. To assess:
• paramedic uptake and satisfaction with the training package
• paramedic compliance with treatment protocol
• safety and acceptability of the intervention to patients and paramedics
RCT feasibility. To clarify primary and secondary outcome measures for full trial and assess:
• trial recruitment, randomisation, and data collection processes
• sample size requirements and attrition rates
• availability of outcome data
Full trial planning. To assess our findings against our progression criteria and, if met, draft a full trial protocol 
and application for funding.
Methods
The protocol for this feasibility study has been  published15. Ethical approval was granted by Wales Research Ethics 
Committee 4, reference 17/WA/0186, and the trial registered on the ISRCTN database (ISRCTN36856873) on 
16/05/2017. Research has been conducted in accordance with the Declaration of Helsinki. The design of the trial 
is a single-centre randomised parallel-group feasibility trial, with 1:1 allocation ratio. Patients were eligible if they 
were adult (18 years or over), with severe sepsis (see additional file for our Sepsis Screening Tool), and attended 
by a study paramedic within the catchment area of the participating trial hospital. Patients were excluded if they 
were known or thought to be pregnant, or known to be allergic to antibiotics.
The study was conducted in the Cardiff & Vale of Glamorgan area of Wales, UK. Welsh Ambulance Service 
paramedics based at the five ambulance stations operating in the geographical catchment area of the University 
Hospital of Wales (UHW) were invited to take part. Data were collected from Patient Clinical Records (PCRs) 
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completed by study paramedics, and supplemented by entries made in the PhRASe study logbook, which was 
secured in the resuscitation area of the ED.
Interventions. If the patient was randomly allocated to usual care, the paramedic would provide the patient 
with oxygen to maintain saturations over 94% (88–92% if known to have chronic obstructive pulmonary dis-
ease) and administer 250 ml boluses of 0.9% sodium chloride (up to 2000 ml if the patient is hypotensive e.g. 
systolic blood pressure less than 100 mmHg). If the patient’s clinical condition was judged as serious or critical, 
paramedics could pre-alert the receiving hospital so that the patient could be taken directly to a resuscitation 
bay. If the patient was randomly allocated to experimental care, usual care would be supplemented by collec-
tion of blood cultures, and IV administration of 2 g cefotaxime. Participating paramedics were trained in use of 
this new protocol in small, face to face group sessions, conducted by the Paramedic Research Support Officer 
(PRSO).
Patient consent. Given the potential for severe sepsis to impair mental capacity and the need to provide 
urgent treatment, in accordance with the Mental Capacity Act 2005, we sought approval from the Research 
Ethics Committee to enrol patients prior to obtaining written informed consent for the  research16. At the time 
of paramedic attendance, therefore, patients were only asked to provide consent to treatment—to have blood 
cultures collected and receive antibiotics, if randomly allocated to the intervention arm.
Patients included in the feasibility trial were sent a Patient Information Leaflet, which included a ‘Participant 
Dissent Form’ at 90 days after the patient’s emergency call (30 days for those recruited in the last two months of 
the study), offering options to either decline to receive any further correspondence from the study or to have all 
of their records withdrawn from the study. We included public contributors in discussions about this approach 
which minimises intrusion and possible distress.
Data collection. Routine ambulance service records were used for all prehospital information. Anonymised 
data relating to clinical outcomes and hospital diagnoses were obtained from hospital records as well as through 
the Secure Anonymised Information Linkage (SAIL)  databank18. The SF-12 and Quality of Care Monitoring 
forms were sent out to participants at 90 days (30 days for participants recruited in the last two months of the 
study) along with the Patient Dissent Forms to be returned directly to the research team at Swansea University 
for data entry. Returned questionnaire responses were linked to the anonymised data for analysis within the 
SAIL gateway.
Adverse events. After consultation with the Trial Management Group (TMG) and Trial Steering Committee 
(TSC), it was decided that deaths and Intensive Care Unit (ICU) admissions were expected and would not be 
collected as adverse outcomes. Serious Adverse Reactions (SARs) to be monitored were agreed as:
• Anaphylaxis
• C. difficile infection
• Extravasation at the site administration of antibiotics
• Infection/cellulitis at the site of blood culture collection/administration of antibiotics
• Vascular damage at the site of blood culture collection/administration of antibiotics
Missed recruitments. As part of this feasibility study, we monitored missed recruitments in order to assess 
whether paramedics were able to accurately recognise patients with sepsis; whether paramedics were compli-
ant with the protocol; and how many patients could not be randomised owing to exclusion criteria emergency.
Progression criteria. At the outset of the feasibility trial, the Trial Management Group (TMG) specified 
progression criteria, to be met within reasonable limits; if a progression criterion was within 5% below target we 
would review reasons for this and consider modifications to protocol; if within 10% we would critically review 
reasons for this and assess whether major changes to protocol are likely to improve the issue; if more than 10% 
we should consider whether progression to full trial is appropriate.
Intervention feasibility. 
1. Compliance with protocol by paramedics—>  = 80% of patients recognised as eligible by study paramedics are 
randomly allocated to trial arm
2. Acceptability of intervention to patients—mean patient satisfaction in intervention group > 80% in the control 
group
3. Safety – number of patients who experience adverse events has a difference of < 10% between trial arms
4. Recognition of sepsis –
  a. > 50% of patients with sepsis who are attended by study paramedics are recognised as eligible for the 
study
  b. > 70% of randomised patients are diagnosed with sepsis in hospital
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RCT Feasibility. 
5. Acceptability of RCT to paramedics—≥ 60% of eligible paramedics agree to take part in the study.
6. Acceptability of RCT to patients – dissent to take part in the study is ≤ 30%.
7. Retrieval of outcomes—follow up data for primary outcome can be collected for ≥ 70% of patients.
8. Equipoise—findings indicate that we remain in equipoise about the effectiveness of paramedic obtained blood 
cultures and prehospital antibiotics for sepsis.
9. Recruitment—recruitment target met to ≥ 80%.
Sample size. Paramedics recruited patients over a six-month period. Based on data regarding throughput of 
sepsis cases in ED, we estimated recruitment of approximately 100–150 patients. In this feasibility study we did 
not aim to detect differences between the intervention and control groups in outcomes, but to include enough 
patients to assess findings against our progression criteria.
Randomisation. A randomisation schedule with a 1:1 ratio of ‘intervention’ or ‘control’, stratified by para-
medic was produced by a statistician not involved in the data collection, management or analysis of the data set. 
A unique set of scratchcards with allocation concealed was issued to each study paramedic and kept on their per-
son during each working  shift19. When the study paramedic identified an eligible patient, they were instructed 
to use the next sequential scratchcard from their set out of sight of the patient. The unique number shown on 
the scratchcard became the patient’s Study ID. The paramedic retained the scratchcard in order to store it with 
the randomisation log at the nurses’ station in the Emergency Department, so that the Paramedic Research Sup-
port Officer (PRSO) was able to monitor randomisation. Owing to the nature of the intervention, the outcome 
of randomisation could not be blinded to the paramedics, patients, PRSO or data manager. The allocation was 
concealed from the statistician and health economist until the code for analysis was finalised.
Health economics. The health economic component of this feasibility study focused on establishing the 
main cost drivers by estimating the intervention implementation cost through discussions with the trial team 
and research paramedics, using standard unit costs for the antibiotics given. We considered a suitable framework 
to undertake a full cost-effectiveness analysis in a future trial.
Analysis. We analysed study data to inform progression decision and trial planning: we analysed continu-
ous outcomes (e.g. SF-12 Score; length of stay) by t tests, or non-parametric equivalents; we report mean and 
standard deviation, or median and interquartile range, along with 95% confidence intervals. We analysed binary 
outcomes (e.g. mortality, presence of sepsis) by chi-squared tests; and report proportions and 95% confidence 
intervals. We conducted exploratory analysis of potential primary outcomes to assess whether we had met pro-
gression criterion 8 (whether we remain in equipoise), and to help decide what might be the most appropriate 
primary outcome for a fully-powered trial. We report against each of our progression criteria to inform whether 
we should seek further funding for an appropriately powered trial and provide estimates for performing a power 
calculation for a fully-powered trial. Analysis was performed using SPSS Version 25 and reporting follows rel-
evant CONSORT  checklists20,21.
Public and patient involvement. Public and patient representatives contributed to designing, delivering, 
overseeing and disseminating the study. We recruited people with experience of sepsis, as either patients, car-
ers or family members of patients, to the Trial Management Group and Trial Steering Committee. We provided 
briefing sessions prior to all meetings.
Changes after the study began. Owing to low response rates to study questionnaires, we submitted a 
substantial amendment to the Research Ethics Committee to allow us to conduct the questionnaire by telephone 
if the postal questionnaire had not been returned.
Ethics approval. Ethical approval was granted by Wales Research Ethics Committee 4, reference 17/
WA/0186.
Results
We report feasibility study findings in accordance with relevant CONSORT and GRIPP 2-SF  checklists21,22; the 
CONSORT flowchart is seen in Fig. 1.
Baseline characteristics. Table 1 shows patients’ baseline characteristics. Sixty-two patients (54%) were 
allocated to the intervention arm. The mean age of the intervention arm was 75.6 years (range 30–99) and 38 
patients (61%) were female. The mean age of the control arm was 71.2 years (range 28–97); 33 (65%) control par-
ticipants were female. qSOFA scores (which predicts risk of in hospital mortality, with 3 being the highest risk) 
show that more patients had scores of 2 or 3 in the intervention group, though this wasn’t statistically significant. 
Nine patients in the control group (18%) and 17 in the intervention group (28%) were already taking antibiotics 
at the time of their emergency call.
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Figure 1.  CONSORT flowchart.
Table 1.  Baseline characteristics.
Characteristic Intervention (n = 62) Control (n = 52)
Age in years, mean (range) 75.6 (30–99) 71.2 (28–97)
Female, n (%) 38 (61%) 33 (65%)
qSOFA score, n (%)
0 5 (8.1) 2 (3.8)
1 38 (61.3) 34 (65.4)
2 15 (24.2) 11 (21.2)
3 3 (4.8) 1(1.9)
N miss (%) 1 (1.6) 4 (7.7)
Already taking antibiotics at emergency call, n (%) 9 (18) 17 (28)
6
Vol:.(1234567890)
Scientific Reports |        (2021) 11:18586  | https://doi.org/10.1038/s41598-021-97979-w
www.nature.com/scientificreports/
Recruitment, consent and response rates. Seventy-four of the 104 (71.2%) eligible paramedics who 
worked in the locality at the start of the study agreed to take part, and 54 (73%) completed their training. The 
majority of paramedics recruited at least one patient to the trial (n = 39) with most of them recruiting <  = 3 
patients (n = 26) and the maximum number of patients recruited by one paramedic being seven.
Patients were recruited from 1.12.17 to 31.5.18. In total, 118 patients were randomly allocated to the two trial 
arms; four patients subsequently dissented to be included in the trial, leaving 114 patients recruited to follow-up. 
Two patients (one from each arm of the trial) requested no further correspondence so we collected data from 
their medical records only. We matched 100% of patients to SAIL records. Twenty-three completed questionnaires 
were returned out of 82 (28%) sent to participants who had not died before 90 days (12 of 41 (29%) control and 
11 of 41 (27%) intervention).
The diagnoses recorded in the ED notes showed 51 of the 114 (45%) recruited patients were diagnosed with 
sepsis. Thirty-nine of the 114 (34%) patients were recorded as having a non-viral infection, most commonly 
pneumonia or urinary tract infection. Thus, 90 out of the 114 (79%) recruited patients had sepsis or a likely 
bacterial infection recorded in ED. No serious adverse reactions were recorded.
Accuracy of recognition of sepsis by paramedics. By assessing records from the ED of patients who 
were treated in the resuscitation department for suspected sepsis (as documented in the ED resuscitation log 
book), we recorded 41 patients as ‘missed recruitments’ (meaning there were 159 eligible patients in total). In 13 
of the missed recruitments, the patient was not recognised as having sepsis. In the other 28 missed recruitments, 
who were recognised as having sepsis but not randomly allocated to the trial, reasons cited included lost or for-
gotten scratchcards (n = 9); no PhRASe kit on the vehicle (n = 2); lack of time (n = 2); forgot to enter in the study 
(n = 2); unsafe/unable to cannulate (n = 4); and ‘other’ (n = 9). This means that 118 of 159 total eligible patients 
were allocated to trial arms (74%), and 118 out of 146 patients recognised as eligible by the study paramedic were 
allocated to trial arms (81%).
Protocol deviations. Eighteen protocol deviations were recorded (Table 2). All three patients who were 
initially not recorded in the randomisation log were identified from WAST clinical records and included in fol-
low up. One patient was taken to a non-study hospital as a result of a hospital divert protocol being implemented 
during a period of high demand at the ED.
Health economics. Intervention implementation costs included paramedic training costs and total callout 
costs (including antibiotics and blood cultures in the intervention group). Fifty-four paramedics were trained in 
two 1.5-h sessions (online and face-to-face training) at a total cost of £8,128.50. This amounts to £68.89 per trial 
participant (n = 118). Per-patient training costs are subject to economies of scale and maydecrease if the inter-
vention is on a larger scale. Additionally, total callout costs (comprising staff cost based on time from callout to 
arrival at hospital, cost of cefotaxime 2 g for intravenous  administration16 and laboratory cost of blood  culture17 
were £23.33 (95% CI: -2.71 to 49.36; p = 0.09) higher in the intervention group, based on the additional drug and 
culture costs and an on average 10.2 min (95% CI − 9.0 to 29.4; p = 0.11) longer job cycle time.
Healthcare resource use data linked through the SAIL databank were available for all participants and showed 
that the main cost drivers can be expected to be inpatient admissions and ICU stays (Table 1). There was evidence 
of significant missing SF-12 data with only 23 patients (20.18%) returning completed questionnaires at 90 days.
Outcome analyses. Unadjusted comparisons (seen in Table  3) between deaths; ICU admissions; ED 
attendances in the three months following the initial emergency call; length of hospital admission; job cycle and 
on-scene times satisfaction with care; and health-related quality of life showed no differences at the P = 0.05 level 
of significance. The only statistically significant difference between trial arms was the number of hospital admis-
sions in the three months following the initial emergency call (87 in the experimental arm compared with 56 in 
the usual care arm, p = 0.0002).
Table 2.  Protocol deviations.
Deviation n
Allergy to antibiotics identified after the patient was randomly allocated (no antibiotics given) 4
Lost or damaged scratchcards 4
Patient not recorded in randomisation log 3
Missing kit or component 2
Blood culture forms not completed 1
Incomplete dose of Cefotaxime administered 1
Scratchcards used out of order 1
Control patient given intervention 1
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Sample size and recruitment required for a full trial. We have calculated the sample size required to 
find a 5% difference in mortality between groups, using 90% power and 5% significance, a difference agreed by 
the research team including PPI representatives and clinicians as important. Based on a 90 day mortality rate of 
approximately 28% in this feasibility trial, 3200 patients are needed in analysis. If approximately 10% of partici-
pants dissent from anonymised follow up of routine records, and we are unable to match 1% of cases in routine 
health data sources, we will need to randomly allocate 3591 patients. Using the PhRASe rate of recruitment and 
data on sepsis related calls from potential collaborating ambulance services, we will need five sites to each recruit 
approximately 718 patients during a 24 month recruitment period.
Results summary—Fulfilment of Progression Criteria. This feasibility study met all of its pre-deter-
mined progression criteria, as summarised in Table 4.
Discussion
The PhRASe feasibility study achieved all of its progression criteria within reasonable limits (Table 4).
With regard to acceptability of the RCT to paramedics, more paramedics initially expressed an interest in 
taking part than completed training. It is not known why this was; we would need to consider what the barriers 
to participation were in order to assess whether this could be improved upon in a definitive trial. Though this 
feasibility trial invited paramedics to volunteer, we would in future try to recruit all paramedics in order to meet 
the required sample size.
As there was a 13% absolute difference in 90-day mortality between trial arms, we recommend that in a 
definitive trial mortality is monitored continuously, and reported on a monthly basis, to the independent Data 
Monitoring Committee.
On four occasions, patients were entered into the trial and subsequently found to have an allergy to antibiot-
ics. We would have to further emphasise in training for a definitive trial that the patient’s drug allergies should 
be checked prior to patient recruitment.
Although the recently published PHANTASi  trial23 of prehospital antibiotics in the Netherlands found that 
nurses giving antibiotics in the ambulance did not lead to improved survival, there are factors which make it 
Table 3.  Unadjusted analysis of outcomes between groups. M mean, med median, min minimum, max 
maximum, sd standard deviation, n miss number of missing.
Outcome Intervention (n = 62) Control (n = 52) Total (N = 114) Difference (95% CI, Significance level)
Routine data (SAIL)








Number of ED attendances up to 90 days from emergency call (mean, SD 
of ED attendance per patient) 79 (1.3, 0.5) 76 (1.5, 0.7) 155 (1.4,0.6)
Mean Diff
− 0.2 (− 0.41, 0.03), p = 0.1
Number of hospital admissions up to 90 days from emergency call 
(mean, SD admission per patient) 87 (3.5, 3.3) 56 (1.8,1.0) 143 (2.83, 2.7)
Mean Diff
1.8 (1.0, 2.5). p = 0.00
Bed days used up to 90 days from emergency call (mean (95%CI), 




4, 25.6 − 0.3 (− 8.9, 8.5), p = 0.9
Data collected by PRSO
Time interval (minutes) from emergency call to administration of antibi-
otic m, sd, nmiss(%) 131, 147, 15 (24.2) NA NA NA
Job cycle time (minutes) from time of call to arrival at hospital m, sd, 
nmiss(%) 155, 132, 0 136, 87.5, 0 146, 114, 0
18.7 (− 23,9, 61.3)
p = 0.2
On scene time (minutes) m, sd 77.2, 131 65.5, 86.9 71.9, 113 11.7 (− 30.5,53.9)p = 0.3
Blood Culture received 48 NA NA NA




Not possible to identify 5 (10.4)
Patient reported outcome measures






0, (− 7.8, 7.8), p = 1.0
SF-12 score (at 90 days) n = 11 n = 12 n = 23
Physical component score 31.6 (11.2) 35.3 (12.6) 33.5 (11.8) 3.6, (− 6.7,13.9), p = 0.5
Mental component score
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different to our proposed study. The PHANTASi trial included patients with all severities of sepsis; the overall 
mortality rate was just 8% at 28 days (compared to 28% at 90 days in this feasibility study). The study was there-
fore underpowered to detect a difference in mortality in only those patients with severe sepsis. Ambulances in 
the Netherlands are staffed by nurses with years of experience in treating critically ill patients and who have 
followed additional specialised training before applying to qualify as a registered ambulance nurse. This research 
team proposes to conduct a randomised trial for patients with more severe illness, in an EMS system staffed by 
paramedics rather than nurses.
Weinberger et al.24 discuss the difficulties in assessing time to first antibiotics in patients with sepsis, as 
patients contact emergency services (or their family doctor or out of hours services) at different time points 
in their illness. Though we accept this is true, as we plan to conduct an RCT, the range of time patients’ have 
waited before calling emergency services should not systematically vary between groups. Weinberger et al. also 
argue that patients with multiple comorbidities may not present with typical symptoms of sepsis, as would an 
otherwise healthy person, which could prolong their wait for antibiotics. Again, there is no reason to believe 
one randomised group would have significantly more unwell patients in it, but, for this reason, we would ensure 
comorbidities are included as covariates in the multivariate analysis of outcomes in the full RCT.
Limitations. Patient quality of life data using the SF-12 questionnaire were only obtained from 23 of 82 eligi-
ble participants (28%). While this had to be expected considering the health status of the population in question, 
the lack of response to the SF-12 quality of life questionnaire would need to be addressed in order to undertake a 
cost-utility analysis. This may include investigating barriers for questionnaire completion and putting into place 
measure to improve return rate of outcome measures.
Interpretation and conclusion. We compared trial arms only to confirm that we remain in equipoise 
about the clinical effectiveness of pre-hospital antibiotics for sepsis administered by paramedics. Hence, we treat 
observed differences in outcomes with caution in this feasibility trial.
This feasibility study met its pre-determined progression criteria; an application will therefore be prepared 
and submitted for funding for a fully-powered multi-centre randomised trial.
Trial status. Complete and reported to the funder in June 2019.
Data availability
Study data is available upon request.
Received: 28 April 2021; Accepted: 17 August 2021
Table 4.  Summary of results against progression criteria.
Progression criterion Relevant result Interpretation
1: Compliance with protocol by paramedics—no less than 80% of 
patients recognised as eligible patients by study paramedics are 
randomised
118 of 146 (81%) eligible patients were recruited and randomly 
allocated to trial arm Criterion met
2: Acceptability of intervention to patients—mean patient satisfac-
tion in intervention group is not less than 80% of patient satisfaction 
in the control group
There was no evidence of any difference between groups in patient 
satisfaction Criterion met
3: Safety—number of patients who experience adverse events has a 
difference of less than 10% between trial arms
No adverse reactions were reported. There were no statistically 
significant differences between intervention and control groups in 
Serious Adverse Events (ICU admissions; deaths)
Criterion met
4: Recognition of sepsis—a. at least 50% of patients with suspected 
sepsis who are attended by study paramedics are recognised as 
eligible for the study
118 of 159 (74%) patients who were recorded as having sepsis in ED 
were allocated to trial arms Criterion met
4: Recognition of sepsis—b. at least 70% of randomised patients are 
diagnosed with sepsis in hospital
Ninety of 114 (79%) recruited patients were recorded as having 
sepsis or a likely bacterial infection Criterion met
5: Acceptability of RCT to paramedics—at least 60% of eligible 
paramedics agree to take part in the study
Seventy-four of 104 (71%) eligible paramedics who work in the Car-
diff and Vale locality expressed an interest to take part in PhRASe. 
Fifty-four paramedics completed their training (51.9%)
Criterion met within reasonable limits
6: Acceptability of RCT to patients—dissent from taking part in the 
study is 30% or less Dissent to take part in the study was 3% (4/118) Criterion met
7: Retrieval of outcomes—follow up data for primary outcome 
suitable for fully-powered trial can be collected for 70% or more of 
patients
All recruited patients were matched to routine data outcomes in 
SAIL Criterion met
8: Equipoise—findings indicate that we remain in equipoise about 
the effectiveness of paramedic obtained blood cultures and prehospi-
tal antibiotics for sepsis
Only one outcome (number of hospital admissions in three months 
following emergency call) was statistically significantly different 
between trial arms
Criterion met within reasonable limits
10. Recruitment—recruitment target met to at least 80% We allocated 118 patients to trial arms, with 114 ultimately recruited. (Our aim was to recruit 100–150 patients) Criterion met
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